For people that keep saying Breezula is weaker than fin...
    8/20/2020

    From the encyclopedia
    Clascoterone →

    a novel topical treatment that inhibits DHT on androgen receptors

    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    RU58841 →

    a potent but unapproved and potentially problematic topical anti-androgen

    At a glance
    In this general discussion post, the primary subjects mentioned are
    💧 Breezula (topical) 75 mg 4x daily
    💧 RU58841 (topical) 5%
    the tone is 😐 neutral with modest increases in hair counts results.

    Other terms

    Breezula protects hair follicles from both testosterone and DHT, unlike finasteride, which only protects against DHT. This could potentially lead to significant hair regrowth, similar to results seen in transgender individuals using hormone blockers.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community Why are people so negative regarding Clascoterone (Breezula)?

       20 upvotes 4 months ago
      Clascoterone (Breezula) shows promising hair growth results, but skepticism remains due to past disappointments with new treatments. It may be a good alternative for those who can't tolerate finasteride or dutasteride, and can potentially be combined with them and minoxidil for better results.

      community Stopping fin after 1.8 Years??!!

      in Finasteride/Dutasteride  10 upvotes 9 months ago
      The user is considering stopping finasteride after 1.8 years due to concerns about side effects and is exploring alternatives like minoxidil and topical finasteride. They are also considering microneedling and are advised to wait for new treatments like breezula/clascoterone.

      community Breezula 6 Month Topline Phase III Results Released

       172 upvotes 9 months ago
      Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

      community This could be it!!! New treatment increase hair 500%

       340 upvotes 9 months ago
      Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.

    Related Research

    6 / 6 results
      Antiandrogens and Androgen Inhibitors in Dermatologic Treatments

      research Antiandrogens and Androgen Inhibitors

      November 2020 in “Elsevier eBooks”
      This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.
      Androgenetic Alopecia: An Update Of Treatment Options

      research Androgenetic Alopecia: An Update of Treatment Options

      110 citations , August 2016 in “Drugs”
      Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
      New Therapeutics in the Management of Androgenetic Alopecia

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
      Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris

      research Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris

      7 citations , December 2019 in “American Journal of Clinical Dermatology”
      This review discusses the potential efficacy of topical antiandrogen therapies for treating androgenetic alopecia and acne vulgaris, finding promising results but highlighting the need for more comprehensive studies.